In biomedical research and biomanufacturing, the purity of reagents directly impacts the reliability of experimental outcomes and the safety of downstream therapeutic products. Endotoxins are notorious contaminants in protein preparations. Even trace amounts of endotoxin in recombinant proteins can trigger potent immune responses, distort results, and compromise patient safety, especially in sensitive applications such as immunology, cell and gene therapy, and vaccine production. Sino Biological has addressed this urgent need with the launch of ProPure™, an advanced line of endotoxin-free recombinant proteins.
FDA approves atezolizumab–lurbinectedin for ES-SCLC
Latest NewsThe U.S. FDA has approved atezolizumab and atezolizumab with hyaluronidase in combination with lurbinectedin as the first and only first-line maintenance therapy for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after induction therapy with atezolizumab, carboplatin and etoposide.
New Chief Scientific Officer has started
AppointmentsTessellate Bio (Naarden, Netherlands; Stevenage, UK) appointed Dr Katie Chapman as Chief Scientific Officer (CSO) at the end of September. She succeeds Dr Jürgen Moll, who will be available to the company in an advisory capacity.
Pharma Tariffs: US Government backtracks
Latest NewsAfter the surprising announcement of a 100% tariff on all prescription drugs imported into the United States, the US government appears to be backtracking. Within a few days, its trade policy stance towards the pharmaceutical industry has shifted fundamentally.
The Bridge to your success
slider, Sponsored PublicationsCustomized Enzymes and Reagents from New England Biolabs. Creating the right partnership is essential when pioneering a new life science product.
Biologics CDMO Rezon Bio leaves stealth mode
Latest NewsRezon Bio has launched as a European contract development and manufacturing organisation (CDMO) for biologics. The new company has been created following the demerger of Polpharma Biologics into two independent companies.
ProPure™: Raising the Bar in Life Science Research
slider, Sponsored PublicationsIn biomedical research and biomanufacturing, the purity of reagents directly impacts the reliability of experimental outcomes and the safety of downstream therapeutic products. Endotoxins are notorious contaminants in protein preparations. Even trace amounts of endotoxin in recombinant proteins can trigger potent immune responses, distort results, and compromise patient safety, especially in sensitive applications such as immunology, cell and gene therapy, and vaccine production. Sino Biological has addressed this urgent need with the launch of ProPure™, an advanced line of endotoxin-free recombinant proteins.
Genmab swallows Merus in US$8bn deal
Latest NewsDanish Genmab A/S has acquired the Dutch oncology specialist Merus NV for US$8bn in cash. The 41% premium over Merus’s share price at Friday is largely attributed to the bispecific EGFR x LGR5 antibody, Petosemtamab
MSD Secures Option on EVX-B3
Latest NewsDanish Evaxion A/S hat optionally licenced its vaccine EVX-B3.developed with its AI-Immunology™ platform to Merck, Sharp & Dohme. MSD payed UIS$7.5m upfront and offers up to US$592m in milestone payments plus royalties on net sales.
Trump Targets Overseas with 100%-Tariff
Latest NewsOvernight, US President Donald Trump broke previous tariff agreements with the United Kingdom and the EU, announcing that from 1 October, patented medicines not produced in the US will be subject to a 100% tariff.
UniQure’s stocks up after AMT-130 trial win
Latest NewsAmsterdam-based UniQure NV’s stocks made a 240% after-hours jump at Nasdaq after the company announced its Huntington gene therapy AMT-130 met the endpoints of a Phase II study and it will apply for marketing authorisation next year. In addition, UniQure entered into a US$175m non-dilutive senior secured term loan facility with Hercules Capital and commenced a US$200m underwritten public offering of its ordinary shares to prepare a BLA in Q1 2026.